Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Exelixis
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT04953104CT.gov ARID1A and/or KDM6A Mutation and CXCL13 Expression | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Relatlimab (this asset) | Exelixis | P2 | B · 60 |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Vasgene Therapeutics, Inc | P2/3 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | BB |
| Pembrolizumab | Sutro Biopharma, Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P3 | BB |
| Retifanlimab | Incyte Corporation | P2 | BB |
| Docetaxel | NuCana plc | P3 | BB |
+42 more in the Urothelial Carcinoma cohort
Other indications for Relatlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | BB · 68 |
| Cutaneous Melanoma | — | P3 | BB · 66 |
| Metastatic Melanoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideBeijing BiotechBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncBB
- DurvalumabAlliance for Clinical Trials in OncologyBB
- PembrolizumabSutro Biopharma, Inc.BB
- Cis-Diamminedichloroplatinum IiNagoya UniversityBB
Citation
Floatz Terminal. Relatlimab in Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/relatlimab-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →